{"id":3920,"date":"2026-06-12T10:09:07","date_gmt":"2026-06-12T08:09:07","guid":{"rendered":"https:\/\/hepatoscope.com\/?p=3920"},"modified":"2026-06-17T18:45:37","modified_gmt":"2026-06-17T16:45:37","slug":"risk-stratification-of-masld-related-advanced-fibrosis-using-a-novelpoint-of-care-device-the-hepatoscope","status":"publish","type":"post","link":"https:\/\/hepatoscope.com\/fr\/risk-stratification-of-masld-related-advanced-fibrosis-using-a-novelpoint-of-care-device-the-hepatoscope\/","title":{"rendered":"Risk stratification of MASLD-related advanced fibrosis using a novelpoint-of-care device: the Hepatoscope"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Cyrielle Caussy, Bruno Verg\u00e8s <\/span><\/span>, Fabien Subtil, Amna Abichou-Klich, Val\u00e9rie Hervieu, Damien Leleu, Laurent Miloti, B\u00e9r\u00e9nice S\u00e9grestin, Sylvie Bin, Julien Berthiller, Alexia Rouland, Dominique Delaunay, Claire Primot, Samy Hadjadj, Bertrand Cariou, Philippe Moulin, Sybil Charri`ere, Emmanuel Disse\u00a0<\/p>

\u00a0<\/span><\/p>

\u00a0<\/span><\/p>

WFUMB Ultrasound Open 2, October 202<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

Abstract<\/h2>
Aim: Patients with type 2 diabetes (T2D) and obesity are at increased risk of metabolic dysfunction-associated steatotic liver disease (MASLD) with advanced fibrosis (AF), requiring systematic non-invasive assessment using liver stiffness measurement (LSM) or the ELF test. However, access to these biomarkers remains limited in diabetology. We therefore evaluated the diagnostic performance of a new point-of-care ultrasound device, Hepatoscope, for the risk stratification of AF.<\/div>
\u00a0<\/div>
Methods: Participants with T2D and\/or obesity and MASLD age 40\u201380 years, BMI <40 kg\/m2 prospectively included in a multi-centre study (NCT04435054) underwent LSM using vibration controlled transient elastography (LSM-VCTE, FibroScan) and 2D-transient elastography (LSM-2DTE) using Hepatoscope version 1 and ELF. Post acquisition reprocessing of the LSM-2DTE data using the CE approved version 2 (LSM-2DTE-2) was performed in a subgroup of n = 120 participants. The area under the ROC curve (AUROC) and 95% confidence interval (CI) were assessed for the detection of intermediate to high-risk of AF, defined by LSM-VCTE \u2265 8 kPa.<\/div>
\u00a0<\/div>
Results: Among 294 participants (83.3% T2D, 42.5% female, 71.4% obesity), 24.8% had LSM-VCTE \u2265 8 kPa. Significant correlation was observed between LSM-VCTE and LSM-2DTE-1 r: 0.37 [0.26\u20130.47], P < 0.001 and was higher between LSM-VCTE and LSM-2DTE-2: r: 0.61 [0.47\u20130.71], P < 0.001. In the subgroup of 120 participants, the AUROC (95%CI) of LSM-2DTE-2 for the detection of LSM-VCTE \u2265 8 kPa was 0.81 (0.72\u20130.89) compared to 0.64 (0.52\u20130.75) for ELF.<\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tFull publication here<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Cyrielle Caussy, Bruno Verg\u00e8s , Fabien Subtil, Amna Abichou-Klich, Val\u00e9rie Hervieu, Damien Leleu, Laurent Miloti, B\u00e9r\u00e9nice S\u00e9grestin, Sylvie Bin, Julien Berthiller, Alexia Rouland, Dominique Delaunay, Claire Primot, Samy Hadjadj, Bertrand Cariou, Philippe Moulin, Sybil Charri`ere, Emmanuel Disse\u00a0 \u00a0 \u00a0 WFUMB Ultrasound Open 2, October 202 Abstract Aim: Patients with type 2 diabetes (T2D) and obesity […]<\/p>\n","protected":false},"author":8,"featured_media":3921,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[66,62],"tags":[],"class_list":["post-3920","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peer-reviewed-publications","category-publications"],"acf":[],"_links":{"self":[{"href":"https:\/\/hepatoscope.com\/fr\/wp-json\/wp\/v2\/posts\/3920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hepatoscope.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hepatoscope.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hepatoscope.com\/fr\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/hepatoscope.com\/fr\/wp-json\/wp\/v2\/comments?post=3920"}],"version-history":[{"count":4,"href":"https:\/\/hepatoscope.com\/fr\/wp-json\/wp\/v2\/posts\/3920\/revisions"}],"predecessor-version":[{"id":3925,"href":"https:\/\/hepatoscope.com\/fr\/wp-json\/wp\/v2\/posts\/3920\/revisions\/3925"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hepatoscope.com\/fr\/wp-json\/wp\/v2\/media\/3921"}],"wp:attachment":[{"href":"https:\/\/hepatoscope.com\/fr\/wp-json\/wp\/v2\/media?parent=3920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hepatoscope.com\/fr\/wp-json\/wp\/v2\/categories?post=3920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hepatoscope.com\/fr\/wp-json\/wp\/v2\/tags?post=3920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}